Anti-IL12RB1 antibodies
AssigneeWashington University
InventorsMarco Colonna, Cristiane Secca da Silva
Life of this patent
Estimating the term…
Abstract
The present invention is directed towards isolated antibodies that bind to IL12Rβ1. Specifically, anti-IL12Rβ1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.
Claims18
An anti-IL-12Rβ1 antibody comprising a light chain variable region comprising an L1 comprising the sequence set forth in SEQ ID NO:
- 4, an L2 comprising the sequence YTS, an L3 comprising the sequence set forth in SEQ ID NO:
- 5, and a heavy chain variable region comprising an H1 comprising the sequence set forth in SEQ ID NO:
- 1, an H2 comprising the sequence set forth in of SEQ ID NO:
- 2, an H3 comprising the sequence set forth in SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.